← All Oramed Pharmaceuticals INC filings

Oramed Pharmaceuticals INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ORMP
Oramed Pharmaceuticals INC
10-K: Oramed Pivots to Investments, Advances Oral Insulin Trial
Oramed Pharmaceuticals Inc. reports a significant net income swing in 2025, driven by strategic investment revaluations and a new path for its oral insulin program.
NASDAQ
ORMP
Oramed Pharmaceuticals INC
10-K/A: Oramed Pharmaceuticals Amends 2024 Annual Report to Correct Executive Compensation and Stock Ownership Disclosures
Oramed Pharmaceuticals Inc. filed an amendment to its 2024 Annual Report on Form 10-K to correct disclosures related to Named Executive Officer compensation and security ownership, reflecting revised NEO qualifications and updated certifications.
NASDAQ
ORMP
Oramed Pharmaceuticals INC
10-K: Oramed Pharmaceuticals Inc. Reports 2024 Annual Results, Highlights Strategic Developments
Oramed Pharmaceuticals Inc. files its 10-K, detailing financial results for 2024 and outlining strategic initiatives including a joint venture for oral insulin development and real estate investments.
NASDAQ
ORMP
Oramed Pharmaceuticals INC
10-K: Oramed Pharmaceuticals Amends Consulting and Employment Agreements, Files Annual Report
Oramed Pharmaceuticals has amended consulting and employment agreements with key personnel and filed its annual report, detailing financial results and strategic updates.